A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys with Duchenne Muscular Dystrophy
Phase of Trial: Phase II/III
Latest Information Update: 20 Feb 2019
At a glance
- Drugs Talditercept alfa (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Chugai Pharmaceutical; Roche
- 15 Nov 2018 Planned End Date changed from 17 Dec 2021 to 17 Dec 2024.
- 10 Jul 2018 Planned End Date changed from 30 Jul 2020 to 17 Dec 2021.
- 10 Jul 2018 Planned primary completion date changed from 30 Jul 2020 to 30 Dec 2020.